Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06944145 · ClinicalTrials.gov registry record · Phase 2
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia
A Phase 2 study of BPH (Benign Prostatic Hyperplasia) and Lower Urinary Track Symptoms, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
- 1
- Study location
NCT06944145 is a Phase 2 study of BPH (Benign Prostatic Hyperplasia) and Lower Urinary Track Symptoms that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 242 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06944145, a Phase 2 study of BPH (Benign Prostatic Hyperplasia) and Lower Urinary Track Symptoms, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
- 1
- Study location
Study Summary
SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.
Conditions Studied
Interventions
- DRUG raloxifene
- DRUG Finasteride
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2030-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06944145
The ClinicalTrials.gov registry entry for NCT06944145 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with BPH (Benign Prostatic Hyperplasia) appearing as the primary indexed condition, and to 2 interventions - of which raloxifene is the first listed.
NCT06944145 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06944145 about?
NCT06944145 is a clinical study titled "New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia". SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This proj...
What is the current status of trial NCT06944145?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2025-12-03. Estimated completion is 2030-08-31.
What conditions does trial NCT06944145 study?
This clinical trial studies the following conditions: BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms.
What interventions are being tested in trial NCT06944145?
The interventions under investigation include: raloxifene (DRUG), Finasteride (DRUG).
Who is sponsoring clinical trial NCT06944145?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06944145 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BPH (Benign Prostatic Hyperplasia)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
BPH (Benign Prostatic Hyperplasia)
All registered trials for this condition
Lower Urinary Track Symptoms
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.